APA (7th ed.) Citation

H, T., H, H., K, M., Y, S., Y, O., T, Y., . . . Y, O. (2022). Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: A consecutive analysis of patients having NSCLC with high PD-L1 expression. Cancer immunology, immunotherapy : CII, 71(3), 737. https://doi.org/10.1007/s00262-021-03029-9

Chicago Style (17th ed.) Citation

H, Takumida, Horinouchi H, Masuda K, Shinno Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, and Ohe Y. "Comparison of Time to Failure of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy: A Consecutive Analysis of Patients Having NSCLC with High PD-L1 Expression." Cancer Immunology, Immunotherapy : CII 71, no. 3 (2022): 737. https://doi.org/10.1007/s00262-021-03029-9.

MLA (9th ed.) Citation

H, Takumida, et al. "Comparison of Time to Failure of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy: A Consecutive Analysis of Patients Having NSCLC with High PD-L1 Expression." Cancer Immunology, Immunotherapy : CII, vol. 71, no. 3, 2022, p. 737, https://doi.org/10.1007/s00262-021-03029-9.